Acadia Pharmaceuticals Stock Trading Halted Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Alphabet shares drop ahead of earnings next week
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
Goldman Sachs on Acadia Pharmaceuticals (ACAD): 'We expect the stock to move lower on Tuesday given the results of the vote'
June 21, 2022 10:18 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Neutral rating and $20.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)
The analyst comments "The FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted against pimavanserin (Nuplazid) as an effective treatment for hallucinations and delusions in Alzheimer's disease psychosis (ADP) (Vote: 9 No/3 Yes), and recommended... More
Acadia Pharma (ACAD) Resume Trading, Down 32%
June 21, 2022 7:11 AM EDTAcadia Pharma (NASDAQ: ACAD) Resume Trading, Down 32%
... More


